Navigation Links
caprotec bioanalytics Announces Issuance In Europe of All Core Patents of Its CCMS Technology
Date:2/28/2011

BERLIN, and BURLINGTON, Mass., Feb. 28, 2011 /PRNewswire/ -- caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry (CCMS) technology.  

CCMS offers a novel and direct way to investigate small molecule - protein interactions resulting in a significant functional reduction of proteome complexity. The core of the CCMS technology consists of tri-functional small molecules called Capture Compounds™.  These Capture Compounds enable the direct isolation and identification of selected proteins, including membrane proteins, out of any complex biological sample.

An important application of the CCMS technology is to profile small molecule drug - protein interactions in the human proteome to discover or confirm relevant protein drug targets, the mode of drug action, and off-target proteins potentially causing adverse side effects in humans.

The newly granted European Patent No. EP 1583972 titled "Methods for Identifying Drug Non-targets" covers the use of CCMS technology for lead optimization and risk assessment of candidate drugs to make a go or no-go decision to enter the clinical trial phase.  The European Patent No.  EP  1485707 titled "Compounds and Methods for Analyzing the Proteome" covers Capture Compounds and methods to discover protein biomarkers for diagnostic applications. European Patent No. EP 1502102 titled "Compounds and Methods for Analyzing the Proteome" covers an array-based application of CCMS technology.  Equivalent patents have been issued in many major countries.

"We are pleased about the grant of the last of our three core CCMS patents in Europe, which protect our proprietary technology and endorse the uniqueness of this powerful proteome analysis technology," states Prof. Dr. Hubert Koester, Founder and Chief Executive Officer of caprotec bioanalytics GmbH.  

These new patents are additions to an already significant patent estate of the company in the fields of biopolymer syntheses, functional genomics using ribozymes, and mass spectrometry-based multiplex protein expression analysis.

The company is involved in collaborations applying CCMS technology with pharmaceutical companies to evaluate and optimize drug candidates (see press release from June 28, 2010; "caprotec bioanalytics Announces  the Successful Completion of a Collaborative Research Project With Hoffmann-LaRoche").

About caprotec bioanalytics GmbH

caprotec bioanalytics GmbH was founded by Prof. Dr. Hubert Koester in 2006 and is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of proteomics, drug development and development of protein biomarkers.

The Company holds a vast portfolio of 41 international patents of which 21 are already granted. The technology has been validated through proof-of-principle experiments in all three fields of application and has been described in experimental detail in several peer-reviewed publications.  caprotec is supported by an international scientific advisory board including a Nobel Laureate.

www.caprotec.com


'/>"/>
SOURCE caprotec bioanalytics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
2. caprotec bioanalytics Announces Commercial Launch of Three New caproKits™ for Applications in Functional Proteomics and Drug Development
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson ... Witness , was awarded a $300,000 grant from The Pew Center for Arts ... with ambiguity and the recognition of one’s own limits among health professions students. ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... $5,000 grant from the C. R. Bard Foundation, Inc. to support ... Hills , a service available through the nonprofit home care agency. Using evidence-based ...
(Date:7/21/2017)... ... 21, 2017 , ... In the first prospective ACL reconstruction ... Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain a ... over time. The study, presented today at the American Orthopaedic Society for ...
(Date:7/20/2017)... MA (PRWEB) , ... July 20, 2017 , ... ... form of blood and bone marrow cancer that progresses rapidly without treatment. Newly ... recommended to reduce the chance of reoccurrence and relapse. With such a ...
(Date:7/20/2017)... ATLANTA, Ga. (PRWEB) , ... July 20, 2017 , ... ... and equal access to medicine for everyone affected by diabetes, is teaming up with ... the five-day global event kicks off on July 24th. , “Team Type 1’s ...
Breaking Medicine News(10 mins):